We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Drug Blocks Critical Lung Cancer DNA Repair Enzyme

By LabMedica International staff writers
Posted on 02 Jun 2015
Print article
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
A low molecular weight drug—effective on its own and in combination with radiation therapy—has been developed that interferes specifically with the cell cycle of lung cancer cells.

The drug, RK-33, was developed by investigators at Johns Hopkins University (Baltimore, MD, USA) to block the activity of the RNA helicase, DDX3 (DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked), which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung cancer patients.

The main function of helicases is to unpackage an organism's genes. They are motor proteins that move directionally along a nucleic acid phosphodiester backbone, separating two annealed nucleic acid strands (i.e., DNA, RNA, or RNA-DNA hybrid) using energy derived from ATP hydrolysis. There are many helicases due to the great variety of processes in which strand separation must be catalyzed. The human genome codes for 95 non-redundant helicases: 64 RNA helicases and 31 DNA helicases.

DDX3 is a member of the large DEAD-box protein family, which is defined by the presence of the conserved Asp-Glu-Ala-Asp (DEAD) motif, and has ATP-dependent RNA helicase activity. This protein has been reported to display a high level of RNA-independent ATPase activity, and unlike most DEAD-box helicases, the ATPase activity is thought to be stimulated by both RNA and DNA. This protein has multiple conserved domains and is thought to play roles in both the nucleus and cytoplasm. Overexpression of this gene has been implicated in tumor development.

The investigators synthesized the low molecular weight compound RK-33, which was designed to inhibit DDX3 by binding to the nucleotide-binding site within the enzyme. Results published in the May 2015 issue of the journal EMBO Molecular Medicine revealed that RK-33 binding inhibited DDX3's DNA repair function, which caused tumor cells to die and increased the efficacy of radiation therapy. RK-33 in combination with radiation induced tumor regression in multiple mouse models of lung cancer without causing damage to noncancerous tissues.

“We can lower the dose of radiation significantly but actually get more “bang for your buck” by pretreating lung cancer with RK-33,” said senior author Dr. Venu Raman, associate professor of radiology, radiological science, and oncology at Johns Hopkins University. “DDX3 is an extremely novel target associated with many cancer types and perturbing its function with a small molecule will enhance efficacy for cancer treatment. It is hard to find a magic bullet for cancer treatment, but because RK-33 is nontoxic and is a phenomenal radiosensitizer, there are so many opportunities.”

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.